Avecho hits key Phase III recruitment milestone in CBD insomnia trial

An update from Avecho Biotechnology Limited ( (AU:AVE) ) is now available.

Avecho Biotechnology has completed recruitment of roughly 210 patients for the interim analysis cohort of its pivotal Phase III trial of a TPM-enhanced cannabidiol capsule for insomnia, with results expected in June 2026. The study is intended to support registration with Australia’s Therapeutic Goods Administration and position the company among the first movers in the country’s emerging over-the-counter CBD insomnia market.

The company estimates the Australian over-the-counter CBD opportunity at more than US$125 million annually within a global insomnia market worth over US$5 billion, and has already licensed Australian rights to Sandoz AG on a deal including an upfront fee, milestones and tiered royalties. Management views the interim analysis as a key inflection point that could materially de-risk the program, strengthen Avecho’s strategic position and bolster ongoing licensing discussions for territories outside Australia.

Avecho’s progress comes amid growing recognition of insomnia as a large, under-served condition with significant economic and public health consequences, particularly in Australia where sleep health has been elevated to a national policy priority. A positive readout from the interim analysis would not only validate the company’s TPM-based CBD technology but could also accelerate commercialisation timelines and draw further interest from global pharmaceutical partners seeking exposure to the sleep and CBD markets.

The most recent analyst rating on (AU:AVE) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Avecho Biotechnology Limited stock, see the AU:AVE Stock Forecast page.

More about Avecho Biotechnology Limited

Avecho Biotechnology Limited is an Australian drug-delivery specialist developing human and animal health products using its proprietary Tocopheryl Phosphate Mixture, or TPM, derived from vitamin E to enhance the solubility and absorption of drugs and nutrients. Its lead asset is a TPM-enhanced cannabidiol soft-gel capsule in Phase III clinical development for the treatment of insomnia, targeting both the Australian over-the-counter CBD segment and the broader global insomnia therapeutics market.

Average Trading Volume: 5,914,663

Technical Sentiment Signal: Sell

Current Market Cap: A$33.06M

For a thorough assessment of AVE stock, go to TipRanks’ Stock Analysis page.